vs
Side-by-side financial comparison of Atara Biotherapeutics, Inc. (ATRA) and FATE THERAPEUTICS INC (FATE). Click either name above to swap in a different company.
Atara Biotherapeutics, Inc. is the larger business by last-quarter revenue ($1.6M vs $1.4M, roughly 1.2× FATE THERAPEUTICS INC). On growth, FATE THERAPEUTICS INC posted the faster year-over-year revenue change (-26.4% vs -95.1%). Over the past eight quarters, FATE THERAPEUTICS INC's revenue compounded faster (-15.7% CAGR vs -75.9%).
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.
ATRA vs FATE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $1.4M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | -95.1% | -26.4% |
| Net Profit YoY | 73.2% | 37.9% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $1.4M | ||
| Q3 25 | $3.5M | $1.7M | ||
| Q2 25 | $17.6M | $1.9M | ||
| Q1 25 | $98.1M | $1.6M | ||
| Q4 24 | $32.8M | $1.9M | ||
| Q3 24 | $40.2M | $3.1M | ||
| Q2 24 | $28.6M | $6.8M | ||
| Q1 24 | $27.4M | $1.9M |
| Q4 25 | — | — | ||
| Q3 25 | $-4.3M | $-32.3M | ||
| Q2 25 | $2.4M | $-34.1M | ||
| Q1 25 | $38.0M | $-37.6M | ||
| Q4 24 | $-12.7M | — | ||
| Q3 24 | $-21.9M | $-47.7M | ||
| Q2 24 | $-19.0M | $-38.4M | ||
| Q1 24 | $-31.8M | $-48.0M |
| Q4 25 | — | — | ||
| Q3 25 | -103.5% | -1995.1% | ||
| Q2 25 | 18.2% | -1938.5% | ||
| Q1 25 | 39.5% | -2534.1% | ||
| Q4 24 | -37.3% | — | ||
| Q3 24 | -54.1% | -1703.9% | ||
| Q2 24 | -63.7% | -665.7% | ||
| Q1 24 | -114.2% | -2652.9% |
| Q4 25 | — | — | ||
| Q3 25 | -124.6% | -1852.4% | ||
| Q2 25 | 13.6% | -1786.6% | ||
| Q1 25 | 38.7% | -2309.5% | ||
| Q4 24 | -38.8% | — | ||
| Q3 24 | -54.5% | -1551.0% | ||
| Q2 24 | -66.5% | -567.4% | ||
| Q1 24 | -116.1% | -2493.7% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.32 | $-0.27 | ||
| Q2 25 | $0.19 | $-0.29 | ||
| Q1 25 | $3.50 | $-0.32 | ||
| Q4 24 | $0.27 | — | ||
| Q3 24 | $-2.93 | $-0.40 | ||
| Q2 24 | $-3.10 | $-0.33 | ||
| Q1 24 | $-5.65 | $-0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $203.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.5M | $207.2M |
| Total Assets | $20.2M | $318.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $203.7M | ||
| Q3 25 | $13.7M | $215.4M | ||
| Q2 25 | $22.3M | $222.8M | ||
| Q1 25 | $13.8M | $240.4M | ||
| Q4 24 | $42.5M | $279.1M | ||
| Q3 24 | $67.2M | $296.9M | ||
| Q2 24 | $35.3M | $304.9M | ||
| Q1 24 | $46.2M | $121.3M |
| Q4 25 | $-38.5M | $207.2M | ||
| Q3 25 | $-36.6M | $234.1M | ||
| Q2 25 | $-35.0M | $261.4M | ||
| Q1 25 | $-55.1M | $288.4M | ||
| Q4 24 | $-97.3M | $318.7M | ||
| Q3 24 | $-90.5M | $362.3M | ||
| Q2 24 | $-110.9M | $397.0M | ||
| Q1 24 | $-98.3M | $426.1M |
| Q4 25 | $20.2M | $318.9M | ||
| Q3 25 | $30.2M | $343.7M | ||
| Q2 25 | $36.9M | $371.6M | ||
| Q1 25 | $62.0M | $398.7M | ||
| Q4 24 | $109.1M | $440.7M | ||
| Q3 24 | $142.7M | $495.0M | ||
| Q2 24 | $117.3M | $528.8M | ||
| Q1 24 | $165.3M | $569.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.9M | $-106.1M |
| Free Cash FlowOCF − Capex | — | $-112.0M |
| FCF MarginFCF / Revenue | — | -8183.9% |
| Capex IntensityCapex / Revenue | 0.0% | 434.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-199.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-50.9M | $-106.1M | ||
| Q3 25 | $-9.8M | $-24.4M | ||
| Q2 25 | $-7.3M | $-24.6M | ||
| Q1 25 | $-28.1M | $-33.8M | ||
| Q4 24 | $-24.5M | $-122.9M | ||
| Q3 24 | $-4.0M | $-29.4M | ||
| Q2 24 | $-10.6M | $-32.3M | ||
| Q1 24 | $-29.6M | $-33.4M |
| Q4 25 | — | $-112.0M | ||
| Q3 25 | — | $-26.6M | ||
| Q2 25 | — | $-25.9M | ||
| Q1 25 | — | $-35.0M | ||
| Q4 24 | $-24.6M | $-123.6M | ||
| Q3 24 | — | $-29.9M | ||
| Q2 24 | $-10.7M | $-32.4M | ||
| Q1 24 | $-29.7M | $-33.4M |
| Q4 25 | — | -8183.9% | ||
| Q3 25 | — | -1526.5% | ||
| Q2 25 | — | -1360.7% | ||
| Q1 25 | — | -2148.9% | ||
| Q4 24 | -75.0% | -6645.4% | ||
| Q3 24 | — | -973.1% | ||
| Q2 24 | -37.3% | -477.8% | ||
| Q1 24 | -108.7% | -1736.9% |
| Q4 25 | 0.0% | 434.8% | ||
| Q3 25 | 0.0% | 126.5% | ||
| Q2 25 | 0.0% | 71.4% | ||
| Q1 25 | 0.0% | 73.4% | ||
| Q4 24 | 0.3% | 39.2% | ||
| Q3 24 | 0.0% | 16.1% | ||
| Q2 24 | 0.1% | 0.8% | ||
| Q1 24 | 0.5% | 4.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | -0.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
